SFA Therapeutics, Inc is a clinical-stage, platform-based biotech with a novel immunomodulatory platform focused on chronic inflammatory diseases. Our vision is to change Medicine. SFA is developing small molecule oral drugs that have been shown to modulate the immune system through a complex cascade that affects several important molecular pathways, downregulating NF-kB and RAS. This platform has led to the development of six drugs to treat immuno-inflammatory diseases, targeting psoriasis and liver diseases (Hepatitis B, NASH and Hepatocellular Carcinoma (HCC), the most common form of liver cancer. SFA’s most advanced assets are SFA001 and SFA002, which is in phase 1b.